Search for a clinical trial
Other search option(s)
17 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Terminated trial = 
; Funded by an IRDiRC member = 
; Study involving ERN members in at least two Member States = 
National clinical trial(s)
AUSTRIA
OBERÖSTERREICH
LINZ
INSPIRE: A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent - AT
Ordensklinikum Linz GmbH Elisabethinen
Interne 1 - Hämatologie mit Stammzelltransplantation, Hämostaseologie und medizinische Onkologie
AUSTRIA
SALZBURG
SALZBURG
A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell Carcinoma - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
EB-Haus Austria
AUSTRIA
SALZBURG
SALZBURG
INSPIRE: A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Innere Medizin III
AUSTRIA
WIEN
WIEN
INSPIRE: A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent - AT
Hanusch Krankenhaus
3. Medizinische Abteilung (Hämatologie und Onkologie)
BELGIUM
ANTWERPEN
ANTWERPEN
INSPIRE: A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent - BE
Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Stuivenberg
Hematologie (Bloedziekten)
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent-CA
Institution: Information not provided - CA
ESTONIA
Tallinn
TALLINN
A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physicians Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent (EE)
North Estonia Medical Centre
Oncology and Haematology Clinic
GERMANY
Sachsen
DRESDEN
Phase III multicenter, randomized, controlled study to assess efficacy and safety of ON 01910.Na in MDS Patients with excess blasts relapsing after or refractory to or intolerant to Azacitidine or Decitabine - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
GERMANY
Sachsen
LEIPZIG
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent - DE
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
IRELAND
County Dublin
DUBLIN
INSPIRE: A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent - IE
Tallaght University Hospital
Department of Haematology
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
ONTIME: Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine - IT
Institution: Information not provided - IT
ITALY
PIEMONTE
NOVARA
INSPIRE: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent - IT
Azienda Ospedaliero-Universitaria Maggiore della Carità
S.C. di Ematologia
SPAIN
Andalucía
SEVILLA
INSPIRE: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent - ES (completed)
Hospital Universitario Virgen del Rocío
Unidad de Hematología
SPAIN
Baleares
PALMA DE MALLORCA
A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine - ES (completed)
Hospital Universitari Son Espases
Unidad de Coagulopatías Congénitas
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Blasts Progressing On or After azacitidine or decitabine - ES (Completed)
Institution: Information not provided - ES
SWITZERLAND
Suisse Alémanique
BERN
INSPIRE: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent - CH
Universitätsspital Inselspital
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor (UKH-HZL)
UNITED KINGDOM
Grampian
ABERDEEN